BACKGROUND: Although hepatic insulin resistance has been documented in patients with metabolic syndrome using homeostasis model assessment of insulin resistance (HOMA-IR) as a measure, there is scanty data on adipose insulin resistance (Adipo-IR) and its relationship with the dysregulation of adipokines in metabolic syndrome. Thus, we examined whether Adipo-IR is increased in metabolic syndrome as well as its correlation with circulating adipokines. METHODS: In 42 individuals including controls and participants with metabolic syndrome, we measured fasting plasma insulin and free fatty acids (FFA). Adipo-IR was calculated as the product of FFA×insulin. We examined the association between Adipo-IR, metabolic syndrome variables, and circulating adipokines, including leptin, adiponectin, chemerin, omentin-1, and retinol-binding protein-4. RESULTS: Adipo-IR was higher in metabolic syndrome (n=19; median 68.7 mmol/L·pmol/L; 25(th)-75(th) percentile, 50.0-104.7) compared to controls (n=23; 22.9 mmol/L·pmol/L; 6.8-36.1; P<0.0001), and this difference was similar following adjustments for waist circumference or body mass index (BMI). Adipo-IR correlated significantly with certain adipokines: Leptin, r=0.45, P=0.004; adiponectin, r=-0.33, P<0.05; chemerin r=0.55, P=0.0008; omentin-1, r=-0.46, P=0.04, and with all features of metabolic syndrome. CONCLUSIONS: Adipo-IR is increased in metabolic syndrome following adjustment for adiposity and may be an important biomarker of adipose tissue dysregulation, including adipokine secretion and a potential relevant therapeutic target.
BACKGROUND: Although hepatic insulin resistance has been documented in patients with metabolic syndrome using homeostasis model assessment of insulin resistance (HOMA-IR) as a measure, there is scanty data on adipose insulin resistance (Adipo-IR) and its relationship with the dysregulation of adipokines in metabolic syndrome. Thus, we examined whether Adipo-IR is increased in metabolic syndrome as well as its correlation with circulating adipokines. METHODS: In 42 individuals including controls and participants with metabolic syndrome, we measured fasting plasma insulin and free fatty acids (FFA). Adipo-IR was calculated as the product of FFA×insulin. We examined the association between Adipo-IR, metabolic syndrome variables, and circulating adipokines, including leptin, adiponectin, chemerin, omentin-1, and retinol-binding protein-4. RESULTS: Adipo-IR was higher in metabolic syndrome (n=19; median 68.7 mmol/L·pmol/L; 25(th)-75(th) percentile, 50.0-104.7) compared to controls (n=23; 22.9 mmol/L·pmol/L; 6.8-36.1; P<0.0001), and this difference was similar following adjustments for waist circumference or body mass index (BMI). Adipo-IR correlated significantly with certain adipokines: Leptin, r=0.45, P=0.004; adiponectin, r=-0.33, P<0.05; chemerin r=0.55, P=0.0008; omentin-1, r=-0.46, P=0.04, and with all features of metabolic syndrome. CONCLUSIONS: Adipo-IR is increased in metabolic syndrome following adjustment for adiposity and may be an important biomarker of adipose tissue dysregulation, including adipokine secretion and a potential relevant therapeutic target.
Authors: Shi-Xiong Tan; Kelsey H Fisher-Wellman; Daniel J Fazakerley; Yvonne Ng; Himani Pant; Jia Li; Christopher C Meoli; Adelle C F Coster; Jacqueline Stöckli; David E James Journal: J Biol Chem Date: 2015-02-26 Impact factor: 5.157
Authors: Miguel Ángel Gómez-Sámano; Daniel Cuevas-Ramos; Mariana Grajales-Gómez; Marco Escamilla-Márquez; Angelina López-Estrada; Luz Elizabeth Guillén-Pineda; Guadalupe López-Carrasco; Francisco J Gómez-Pérez Journal: BMJ Open Diabetes Res Care Date: 2017-05-08
Authors: Esteban Jorge-Galarza; Carlos Posadas-Romero; Margarita Torres-Tamayo; Aida X Medina-Urrutia; Marco A Rodas-Díaz; Rosalinda Posadas-Sánchez; Gilberto Vargas-Alarcón; María Del Carmen González-Salazar; Guillermo C Cardoso-Saldaña; Juan G Juárez-Rojas Journal: Dis Markers Date: 2016-12-29 Impact factor: 3.434
Authors: Christine M Kusminski; Violeta I Gallardo-Montejano; Zhao V Wang; Vijay Hegde; Perry E Bickel; Nikhil V Dhurandhar; Philipp E Scherer Journal: Mol Metab Date: 2015-07-26 Impact factor: 7.422
Authors: Jiajia Jiang; Xueli Cai; Yuesong Pan; Xiaoyan Du; Huiping Zhu; Xinghua Yang; Deqiang Zheng; Herbert Gaisano; Tiemin Wei; Yan He Journal: BMJ Open Diabetes Res Care Date: 2020-04